Regeneron Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Regeneron Pharmaceuticals de 10.9% y 6.9% por año respectivamente. Se prevé que el BPA crezca en un 9% al año. Se espera que la rentabilidad financiera sea de 16.7% en 3 años.

Información clave

12.4%

Tasa de crecimiento de los beneficios

11.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.6%
Tasa de crecimiento de los ingresos	7.4%
Rentabilidad financiera futura	16.1%
Cobertura de analistas	Good
Última actualización	16 May 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

WBAG:REGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	15,979	5,164	5,662	5,549	22
12/31/2025	14,929	4,419	5,056	4,730	26
12/31/2024	13,826	3,965	5,244	5,850	26
3/31/2024	13,100	3,858	3,930	4,739	N/A
12/31/2023	13,117	3,954	3,668	4,594	N/A
9/30/2023	13,097	3,991	4,359	5,224	N/A
6/30/2023	12,671	4,299	3,004	4,739	N/A
3/31/2023	12,370	4,183	2,527	4,281	N/A
12/31/2022	12,173	4,338	3,398	5,015	N/A
9/30/2022	13,710	5,370	4,148	5,668	N/A
6/30/2022	14,227	5,687	7,869	8,452	N/A
3/31/2022	16,508	7,934	7,936	8,515	N/A
12/31/2021	16,072	8,075	6,529	7,081	N/A
9/30/2021	13,543	6,996	5,381	5,940	N/A
6/30/2021	12,384	6,205	1,694	2,272	N/A
3/31/2021	9,198	4,004	2,029	2,589	N/A
12/31/2020	8,497	3,513	2,004	2,618	N/A
9/30/2020	7,938	3,156	1,582	2,175	N/A
6/30/2020	7,387	2,984	2,425	2,986	N/A
3/31/2020	7,013	2,279	1,706	2,231	N/A
12/31/2019	6,558	2,116	2,000	2,430	N/A
9/30/2019	6,622	2,144	1,995	2,371	N/A
6/30/2019	6,542	2,069	1,906	2,267	N/A
3/31/2019	6,572	2,428	2,095	2,473	N/A
12/31/2018	5,146	2,444	1,812	2,195	N/A
9/30/2018	6,365	1,798	1,628	2,033	N/A
6/30/2018	6,203	1,591	1,636	1,995	N/A
3/31/2018	6,065	1,428	1,268	1,570	N/A
12/31/2017	5,872	1,199	N/A	1,307	N/A
9/30/2017	5,517	1,278	N/A	1,118	N/A
6/30/2017	5,236	1,155	N/A	1,354	N/A
3/31/2017	4,979	963	N/A	1,784	N/A
12/31/2016	4,860	896	N/A	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A
12/31/2015	4,104	636	N/A	1,331	N/A
9/30/2015	3,808	571	N/A	1,247	N/A
6/30/2015	3,396	444	N/A	519	N/A
3/31/2015	3,063	346	N/A	597	N/A
12/31/2014	2,820	338	N/A	752	N/A
9/30/2014	2,628	345	N/A	831	N/A
6/30/2014	2,499	403	N/A	759	N/A
3/31/2014	2,291	394	N/A	551	N/A
12/31/2013	2,105	414	N/A	589	N/A
9/30/2013	1,909	798	N/A	400	N/A
6/30/2013	1,740	848	N/A	305	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.9% al año) de REGN es superior a la tasa de ahorro (0.9%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.9% al año) de REGN crezcan más rápidamente que el mercado Austrian (3% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de REGN crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6.9% al año) de REGN crezcan más rápidamente que los del mercado Austrian (-2% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.9% al año) de REGN crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de REGN sea baja dentro de 3 años (16.7%).

Regeneron Pharmaceuticals Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold €7.1m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. Announces Two-Year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-Related Macular Degeneration

Second quarter 2023 earnings released: EPS: US$9.05 (vs US$7.90 in 2Q 2022)

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal PHOTON Trial Investigating Aflibercept 8 mg with 12- and 16-Week Dosing Regimens

New minor risk - Share price stability

Regeneron Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

FDA Issues Complete Response Letter (CRL) for Aflibercept 8 Mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings At A Third-Party Filler

Regeneron Pharmaceuticals, Inc. Provides Updated Data from Two Phase 2 Expansion Dose Cohorts Evaluating Investigational Linvoseltamab

First quarter 2023 earnings released: EPS: US$7.64 (vs US$9.12 in 1Q 2022)

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approved Eylea Injection

Full year 2022 earnings released: EPS: US$40.51 (vs US$76.40 in FY 2021)

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Expands the Marketing Authorization for Dupixent® (Dupilumab) in the European Union

Now 20% undervalued after recent price drop

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento